Menu Search
Equities

Shanghai Aohua Photoelectricity Endoscope Co Ltd

688212:SHH

Shanghai Aohua Photoelectricity Endoscope Co Ltd

Actions
Health CareMedical Equipment and Services
  • Price (CNY)51.41
  • Today's Change-0.86 / -1.65%
  • Shares traded1.11m
  • 1 Year change-22.11%
  • Beta--
Data delayed at least 15 minutes, as of Nov 15 2024.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Inc stmt in CNYIncome statement in CNYView more

Year on year Shanghai Aohua Photoelectricity Endoscope Co Ltd grew revenues 52.29% from 445.26m to 678.08m while net income improved 166.42% from 21.72m to 57.85m.
Gross margin68.88%
Net profit margin6.97%
Operating margin6.15%
Return on assets3.26%
Return on equity3.67%
Return on investment3.66%
More ▼

Cash flow in CNYView more

In 2023, Shanghai Aohua Photoelectricity Endoscope Co Ltd increased its cash reserves by 6.25%, or 14.38m. The company earned 37.41m from its operations for a Cash Flow Margin of 5.52%. In addition the company generated 4.34m cash from financing while 27.94m was spent on investing.
Cash flow per share--
Price/Cash flow per share--
Book value per share10.27
Tangible book value per share9.25
More ▼

Balance sheet in CNYView more

Shanghai Aohua Photoelectricity Endoscope Co Ltd appears to have a strong balance sheet and has grown its cash reserves consistently over the last four years to total 244.55m.
Current ratio4.55
Quick ratio3.33
Total debt/total equity0.0897
Total debt/total capital0.0815
More ▼

Growth rates in CNY

Year on year, growth in earnings per share excluding extraordinary items increased 164.03%.
Div yield(5 year avg)--
Div growth rate (5 year)--
Payout ratio (TTM)80.47%
EPS growth(5 years)--
EPS (TTM) vs
TTM 1 year ago		-6.48
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.